Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

Soluble tetra- and pentavalent vanadium substances failed to elicit any skin sensitising response in sensitisation studies according to Magnusson and Kligman (OECD 406). The studies by Haferkorn (2010a,b) are considered key studies on skin sensitisation and are used for classification. Positive human experience with any vanadium substance have not been reported. Based on read-across, potassium vanadium trioxide is not assumed to have a potential for skin sensitisation.

Read across

Upon dissolution, vanadium substances transform inartificial body fluids, including PBS, sweat, gastric juice and lung fluid, predominantly to the pentavalent form,except in artificial lysosomal fluid; here, even pentavalent forms are converted almost completely to tetravalent species already after a short period of time (for more information on in vitro bioaccessibility testing, please refer IUCLID section 7). Thus, it can be assumed that vanadium speciation in body fluids is controlled by the conditions of the respective medium but not by the vanadium source. Thus, read-across of skin sensitisation data from soluble tetra- and pentavalent vanadium substances is justified.

Potassium is (i) ubiquitous in the environment (air, soil and water), (ii) a key nutrient andintrinsically present in the human body due to a natural background in all dietary sources, and (iii) a normal constituent of all body fluids and a main blood mineral, and maintains electrolyte or acid-base (pH) balance as well as a proper fluid. Potassium belongs to the ten most common elements in the human body, by mass ca. 0.4%, and functions in the body cover cellular transport, water regulation, blood pressure control, nerve conduction, muscular contraction as well as enzymatic reactions and other metabolic activities. In consequence, because of the intrinsic nature of potassium as endogenous physiological compound, any skin sensitising effect of potassium is not to be expected. Therefore, only the potential of the respective vanadium anion was addressed by testing.


Migrated from Short description of key information:
Soluble penta- and tetravalent vanadium substances did test negative (i.e. not sensitising) in skin sensitisation studies according to Magnusson and Kligman (OECD 406). A justification for using the Magnusson and Kligman design instead of the LLNA is provided as attached document below. Potassium vanadium trioxide is not considered to have a sensitisation potential.

Justification for selection of skin sensitisation endpoint:
The studies by Haferkorn (2010a,b) are considered key studies on skin sensitisation and used for classification.

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:
Migrated from Short description of key information:
Vanadium exposure has not been reported to induce immune responses in vanadium industry workers, and occupational asthma or reduced lung function have not been diagnosed in vanadium and vanadium substances producing facilities.

Justification for classification or non-classification

Based on the outcome of sensitisation studies with soluble vanadium forms according to Magnusson and Kligman, it can be concluded that potassium vanadium trioxide does not have a sensitisation potential and therefore must not be classified and labelled according to Regulation (EC) 1272/2008.